Tae You Kim

Summary

Affiliation: Seoul National University
Country: Korea

Publications

  1. ncbi Histone deacetylase inhibitors for cancer therapy
    Tae You Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Epigenetics 1:14-23. 2006
  2. ncbi Identification of DNA methylation changes associated with human gastric cancer
    Jung Hoon Park
    Department of Biochemistry, College of Life Science and Technology, Yonsei University, Seoul, Korea
    BMC Med Genomics 4:82. 2011
  3. ncbi Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
    Sun Kyung Baek
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Gastroenterol 11:56. 2011
  4. ncbi Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
    Yun Gyoo Lee
    Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 11:188. 2011
  5. ncbi The role of PET/CT in detection of gastric cancer recurrence
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:73. 2009
  6. ncbi Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
    Ji Hyun Kwon
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
    BMC Cancer 10:557. 2010
  7. ncbi Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
    In Sil Choi
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul 110 744, Korea
    Jpn J Clin Oncol 35:6-12. 2005
  8. ncbi Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:63. 2007
  9. ncbi Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells
    Tai Young Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110 744, Korea
    Oncogene 22:3943-51. 2003
  10. ncbi Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
    Junshik Hong
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Cancer Chemother Pharmacol 67:1323-31. 2011

Detail Information

Publications136 found, 100 shown here

  1. ncbi Histone deacetylase inhibitors for cancer therapy
    Tae You Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Epigenetics 1:14-23. 2006
    ..In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy...
  2. ncbi Identification of DNA methylation changes associated with human gastric cancer
    Jung Hoon Park
    Department of Biochemistry, College of Life Science and Technology, Yonsei University, Seoul, Korea
    BMC Med Genomics 4:82. 2011
    ..Epigenetic alteration of gene expression is a common event in human cancer. DNA methylation is a well-known epigenetic process, but verifying the exact nature of epigenetic changes associated with cancer remains difficult...
  3. ncbi Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
    Sun Kyung Baek
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Gastroenterol 11:56. 2011
    ..In this study, we performed an evaluation of clinicopathologic characteristics, treatment outcome, and prognosis in patients with gastric HAC...
  4. ncbi Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
    Yun Gyoo Lee
    Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 11:188. 2011
    ..This study is to determine the clinical role of 18F-FDG PET/CT during post-operative surveillance of suspected recurrent BTC based on symptoms, laboratory findings and contrast-enhanced CT (ceCT) findings...
  5. ncbi The role of PET/CT in detection of gastric cancer recurrence
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:73. 2009
    ..The purpose of this study is to evaluate the efficacy and usefulness of PET/CT for detecting recurrence of gastric cancer after curative resection...
  6. ncbi Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
    Ji Hyun Kwon
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
    BMC Cancer 10:557. 2010
    ..Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic...
  7. ncbi Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
    In Sil Choi
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul 110 744, Korea
    Jpn J Clin Oncol 35:6-12. 2005
    ..The objectives of the present study were to assess the efficacy and tolerability of perioperative paclitaxel/platinum-based chemotherapy and surgery in patients with stage IIIA clinical N2 (cN2) non-small cell lung cancer (NSCLC)...
  8. ncbi Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:63. 2007
    ....
  9. ncbi Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells
    Tai Young Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110 744, Korea
    Oncogene 22:3943-51. 2003
    ..Taken together, the results of our study suggest that the transcriptional silencing of DLC-1, by epigenetic mechanism, may be involved in gastric carcinogenesis...
  10. ncbi Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
    Junshik Hong
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Cancer Chemother Pharmacol 67:1323-31. 2011
    ..To evaluate the efficacy and safety of S-1 in combination with oxaliplatin in a biweekly schedule as first-line treatment in metastatic colorectal cancer and the association between genetic polymorphisms and treatment outcomes...
  11. ncbi Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy
    Yeonjoo Jung
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 799, South Korea
    J Mol Med (Berl) 85:1137-48. 2007
    ..These results provide a rationale for the development of a DNMT1-targeted strategy as an effective epigenetic cancer therapy...
  12. ncbi Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Cancer Sci 101:793-9. 2010
    ..These results suggest that the EGFR intron 1 CA repeat polymorphism could be a useful, predictive biomarker of cetuximab efficacy in AGC and merits further investigation in randomized studies...
  13. ncbi ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy
    Ji Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    Oncology 83:218-27. 2012
    ..The aim of this study was to elucidate clinical implications of ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer (MBC) after taxane plus trastuzumab (TH) chemotherapy...
  14. ncbi Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
    Hwang Phill Kim
    Cancer Research Institute, Seoul National University College of Medicine, Chongno Gu, Seoul, Korea
    Mol Cancer Ther 7:607-15. 2008
    ....
  15. ncbi Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
    Sae Won Han
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Lung Cancer 54:201-7. 2006
    ..Direct comparison between clinical predictors and EGFR mutation for their predictive power has not been reported...
  16. ncbi Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 77:1186-90. 2010
    ..To analyze the outcome of adjuvant chemoradiotherapy for patients with distal common bile duct (CBD) cancer who underwent curative surgery, and to identify the prognostic factors for these patients...
  17. ncbi Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Tumori 97:280-5. 2011
    ..To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer...
  18. ncbi Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study
    Jin Soo Kim
    Department of Internal Medicine, Seoul National University Hospital, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 41:245-52. 2011
    ..The aim of this study is to evaluate the efficacy of adjuvant chemotherapy with 5-fluorouracil and cisplatin in gastric cancer patients and to assess prognostic factors affecting relapse and survival...
  19. ncbi Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
    BMC Cancer 8:148. 2008
    ..We also analyzed the predictive or prognostic value of germline polymorphisms of candidate genes associated with 5-FU and oxaliplatin...
  20. ncbi The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
    Jong Mu Sun
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Lung Cancer 68:427-32. 2010
    ..We sought to identify the relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer (NSCLC)...
  21. ncbi Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 25:235-9. 2010
    ..A bcl-2(-)/ER(-) phenotype and p53 expression are useful molecular markers predicting loco-regional relapse-free and distant metastasis-free survival, respectively, in patients treated with breast conserving surgery and radiotherapy...
  22. ncbi DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells
    Heesun Kim
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Int J Oncol 36:1563-72. 2010
    ..This study is the first to show that DNMT3L exerts a major effect on the transcriptional regulation of a specific target gene, such as TDG, despite the absence of enzymatic activity...
  23. ncbi Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy
    Hye Suk Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    J Korean Med Sci 24:910-7. 2009
    ..Furthermore, the magnitude of HER2 amplification is an independent predictive factor of TTP...
  24. ncbi Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 84:81-7. 2012
    ..To analyze the prognostic factors predicting distant metastasis in patients undergoing adjuvant chemoradiation for extrahepatic bile duct (EHBD) cancer...
  25. ncbi Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak Ro, Jongno gu, Seoul 110 744, Republic of Korea
    Clin Transl Oncol 14:391-5. 2012
    ..To analyse the outcome of adjuvant chemoradiotherapy for periampullary adenocarcinoma and the impact of tumour location as a prognosticator...
  26. ncbi The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen
    Jin Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University, Seoul, Korea
    Anticancer Res 32:1547-53. 2012
    ..We aimed to clarify the prognostic significance of HER2 positivity in advanced gastric cancer...
  27. ncbi Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy
    Ji Won Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Am J Clin Oncol 34:125-9. 2011
    ..The objectives of this analysis were to investigate efficacy and safety of sorafenib in these patients and to elucidate risk factors associated with clinical outcomes...
  28. ncbi Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
    Sun Young Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Chongro Gu, Seoul 110 799, Korea
    Int J Oncol 32:89-95. 2008
    ..These results suggest that trastuzumab combined with chemotherapeutic agents can be active against gastric cancer with HER2 amplification...
  29. ncbi RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    Cancer Lett 299:22-8. 2010
    ..In conclusion, RAD001 showed growth inhibitory activity against gastric cancer cells and acted synergistically with cytotoxic agents such as 5-FU by downregulating TS...
  30. ncbi TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin
    Hwang Phill Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Tumor Biology, College of Medicine, Seoul National University, Seoul 110 799, South Korea
    Biochim Biophys Acta 1743:151-61. 2005
    ..Therefore, this study represents another mechanism to regulate cell cycle regulators when integrin signaling is collaborative with TGF-beta1 pathways...
  31. ncbi Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital and Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    Pharmacogenet Genomics 17:313-9. 2007
    ..Therefore, CA repeat polymorphism in intron 1 was analyzed for its association with gefitinib responsiveness together with epidermal growth factor receptor mutation in Korean patients...
  32. ncbi Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers
    Jiyeon Yun
    Cancer Research Institute, Seoul National University College of Medicine, South Korea
    Lab Invest 92:1033-44. 2012
    ..Taken together, the results of our study showed for the first time that EREG is epigenetically silenced in gastric cancer cells by aberrant DNA methylation and histone modification...
  33. ncbi Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehang ro, Jongno gu, Seoul, 110 744, Korea
    Breast Cancer Res 13:R22. 2011
    ..The purpose of this study was to identify the predictive or prognostic value of Ki-67 among patients with TNBC treated with neoadjuvant chemotherapy, and the role of Ki-67 in further classification of TNBC...
  34. ncbi Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Cancer Chemother Pharmacol 68:1017-26. 2011
    ....
  35. ncbi Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase
    Jung Hyun Park
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
    J Mol Med (Berl) 86:117-28. 2008
    ..Overall, these provide a novel molecular basis of tumor selectivity of HDI. LAQ824 and SK-7068 might be more effective HDIs in cancer cells with Aurora-A overexpression...
  36. ncbi Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab
    Hye Jung Chang
    Department of Internal Medicine, Seoul National University Hospital, 28 Yongon Dong, Chongno Gu, Seoul 110 744, South Korea
    Jpn J Clin Oncol 41:593-9. 2011
    ..Recent studies have shown that the human epidermal growth factor receptor 2 status of a metastatic site may differ from that of the primary site. This difference may influence patient prognosis and response to therapy...
  37. ncbi DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma
    Tai Young Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110 744, Republic of Korea
    Biochem Biophys Res Commun 355:72-7. 2007
    ..These observations suggest that DLC-1 plays important roles in signal transduction pathway regulating cell proliferation, cell morphology, and cell migration by affecting Rho family GTPases and focal adhesion proteins...
  38. ncbi Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
    Young Kwang Yoon
    Cancer Research Institute, Seoul National University College of Medicine, Korea
    Mol Cancer Ther 8:2526-36. 2009
    ..Our results provide the basis for a rational combination strategy against human EGFR WT gastric cancers, predicated on the understanding of cross-talk between the MEK and EGFR pathways...
  39. ncbi Prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
    Am J Clin Oncol 33:23-7. 2010
    ..To evaluate the prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy...
  40. ncbi Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer
    Jinah Park
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    Invest New Drugs 30:1404-12. 2012
    ..This demonstrates the potential for P-cadherin to be used as a target for treatment of gastric cancer...
  41. ncbi Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
    Young Kwang Yoon
    Cancer Research Institute, Seoul National University College of Medicine, South Korea
    Cancer Lett 316:77-84. 2012
    ..Our study provides a mechanism of differential response to MEK inhibition in KRAS mutant cancer...
  42. ncbi Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer
    Hyun Jin Nam
    Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Jongno gu, Seoul, 110 744, Korea
    Mol Cancer Ther 11:439-51. 2012
    ....
  43. ncbi Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
    Hee Jun Kim
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    J Neurooncol 106:303-13. 2012
    ..Our results suggest that appropriate palliative systemic therapy after WBRT or GKS, and adequate palliative treatment via combined modalities are helpful for breast cancer patients, even after the detection of CNS metastases...
  44. ncbi Aggressiveness of cancer-care near the end-of-life in Korea
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 38:381-6. 2008
    ..The aim of this study was to examine the appropriateness of chemotherapy and care in Korean cancer patients near the end-of-life...
  45. ncbi Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
    Hyun Jin Nam
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    Cancer Lett 302:155-65. 2011
    ..Therefore, HM781-36B may be useful for the treatment of HER2 amplified gastric cancer alone or in combination with chemotherapeutic agents...
  46. ncbi Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy
    Ho Young Yhim
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Cancer 116:2890-901. 2010
    ..The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy...
  47. ncbi Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells
    Ju Hee Lee
    Cancer Research Institute, College of Medicine, Seoul National University, Seoul 110 799, Korea
    Mol Cells 30:107-12. 2010
    ..How TXNIP is preferentially regulated by HDAC10 needs further investigation...
  48. ncbi High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
    Jiyoung Rhee
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Breast Cancer Res Treat 125:107-14. 2011
    ..These data suggest that TGF-α plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer...
  49. ncbi Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells
    Sang Gyun Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110 744, Korea
    Mol Biol Cell 15:420-34. 2004
    ....
  50. ncbi Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul, 110 744 Korea
    J Clin Oncol 23:2493-501. 2005
    ..This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib...
  51. ncbi Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:203. 2007
    ..The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy...
  52. ncbi Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
    Mi Jung Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 8:374. 2008
    ..Fluoropyrimidine or gemcitabine, with or without platinum, are most frequently used. We conducted this study to clarify the efficacy of palliative chemotherapy in BTC...
  53. ncbi Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
    Su Jung Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 10:448. 2010
    ..Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent neuroendocrine tumor (NET) have been few...
  54. ncbi Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 11:452. 2011
    ....
  55. ncbi AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity
    Moon Chang Choi
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongro Gu, Seoul 110 799, Korea
    Oncogene 23:7095-103. 2004
    ..In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer...
  56. ncbi Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    J Cancer Res Clin Oncol 137:1301-8. 2011
    ..The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms...
  57. ncbi Induction chemotherapy followed by radiotherapy in the treatment of anal cancer
    Dae Ho Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    Oncol Rep 10:101-4. 2003
    ..Induction chemotherapy followed by radiotherapy in patients with anal cancer is effective in terms of its response and preserving the anal sphincter without serious acute and late complications...
  58. ncbi Age <40Years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy
    Kyubo Kim
    Departments of Radiation Oncology Surgery Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Breast J 17:75-8. 2011
    ..There was also a trend for inferior DMFS and OS in younger patients. Age at diagnosis should be considered for individualized patient management...
  59. ncbi The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
    Jin Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Cancer Lett 272:296-306. 2008
    ..These results provide a rationale for the future clinical trials of lapatinib combined with cytotoxic drugs in the treatment of HER2-positive gastric cancer...
  60. ncbi Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
    Hyeon Gyu Yi
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Lung Cancer 65:80-4. 2009
    ..Two patients showed responses to higher than standard dose of gefitinib. The median overall survival was not reached. In conclusion, EGFR TKIs are effective in the treatment of LM from NSCLC when patients were selected properly...
  61. ncbi Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Cancer Sci 102:1388-95. 2011
    ....
  62. ncbi Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression
    Sung Hak Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 355:318-23. 2007
    ..These results showed for the first the direct linkage between DNMT and zinc-fingers homeoboxes protein, leading to enhanced gene silencing by DNMT3B...
  63. ncbi The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
    Jiyoung Rhee
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Cancer 8:307. 2008
    ..We investigated the clinicopathologic characteristics and prognostic indicators of lymph node-negative TN breast cancer...
  64. ncbi Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
    Kyu Hyoung Lim
    Departments of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:345. 2009
    ....
  65. ncbi Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer
    Youngil Koh
    Departments of Internal Medicine and daggerPathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
    J Thorac Oncol 5:320-5. 2010
    ..We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1)...
  66. ncbi A-kinase anchoring protein 12 regulates the completion of cytokinesis
    Moon Chang Choi
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 373:85-9. 2008
    ..Our findings implicate AKAP12 in the regulation of cytokinesis progression, and suggest a novel role for AKAP12 tumor suppressor...
  67. ncbi Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehangno, Jongno gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 39:111-5. 2009
    ..The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy...
  68. ncbi Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer
    Do Youn Oh
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Youngon Dong, Chongno Gu, Seoul 110 744, Korea
    Jpn J Clin Oncol 35:380-5. 2005
    ..Our objective was to verify the efficacy and safety of "docetaxel + 5-fluorouracil + cisplatin" 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer...
  69. ncbi Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells
    Keun Wook Lee
    Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Cancer Res 68:1916-26. 2008
    ..Furthermore, enzastaurin had synergistic or additive effects when combined with 5-fluorouracil, cisplatin, paclitaxel, or irinotecan. These results warrant further clinical investigation of enzastaurin for gastric cancer treatment...
  70. ncbi Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer
    Yu Jung Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Cancer Invest 26:152-8. 2008
    ..However, patients with the same stage often have different risks of relapse. Here, we investigated whether the expressions of molecular markers can supplement the current staging system in terms of relapse prediction...
  71. ncbi KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach
    Young Kwang Yoon
    Cancer Research Institute, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 110 744, Korea
    Mol Carcinog 49:353-62. 2010
    ....
  72. ncbi Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Jpn J Clin Oncol 40:112-8. 2010
    ..The aim of this study was to compare the clinical features and prognosis between triple-negative metaplastic carcinoma (TNMC) and non-triple-negative metaplastic carcinoma (NTNMC)...
  73. ncbi Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Tae You Kim
    Seoul National University Hospital, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Expert Rev Mol Diagn 7:821-36. 2007
    ..Several lines of study provided information on various molecular targets for EGFR TKI therapy. A target-based patient-selection strategy is expected to eventually lead to tailored therapy for lung cancer...
  74. ncbi Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
    Jung Hyun Park
    Laboratory for Cancer Epigenetics and Experimental Therapeutics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 368:318-22. 2008
    ..Overall, these results indicate that HDAC6 and HDAC10 play important roles in Hsp-mediated VEGFR regulation...
  75. ncbi VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib
    Youngil Koh
    Department of Internal Medicine, Seoul National University Hospital, Korea
    Diagn Mol Pathol 20:143-7. 2011
    ..However, the genotype did not affect either response rate or the PFS of sunitinib. In conclusion, expressions of VEGF, PDGFR, and CD34 may have predictive value in sunitinib treatments...
  76. ncbi Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study
    Dong Yeop Shin
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehagro, Chongno Gu, Seoul 110 744, Korea
    Cancer Chemother Pharmacol 68:165-75. 2011
    ..We conducted this study to investigate the clinical implication of SUVmax on (18)F FDG-PET as a prognostic factor in patients with HCC, especially in the metastatic setting...
  77. ncbi Negative impact of heat exposure on cosmesis after conservative treatment for breast cancer
    Eui Kyu Chie
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Tumori 93:591-6. 2007
    ..To identify the factors influencing cosmesis after conservative treatment in breast cancer...
  78. ncbi Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul, Republic of Korea
    Breast Cancer Res Treat 116:153-60. 2009
    ..The purpose of this study was to identify the clinical significance of the involved nodal ratios in patients with stage II/III breast cancer treated with neoadjuvant chemotherapy...
  79. ncbi Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer
    Keun Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 22:S115-21. 2007
    ..However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies...
  80. ncbi Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Cancer Chemother Pharmacol 61:47-52. 2008
    ..The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy...
  81. ncbi Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
    Keun-Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno-gu, Seoul 110-744, Republic of Korea
    Jpn J Clin Oncol 35:720-6. 2005
    ..This regimen seems to have comparable efficacy to previously reported higher-dose paclitaxel plus cisplatin-containing regimens and fewer toxicities...
  82. ncbi Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
    Ju-Hee Lee
    Natonal Research Laboratory, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea
    Mol Cancer Ther 5:3085-95. 2006
    ..We conclude that a combinatorial approach using histone deacetylase inhibitors may be useful at overcoming 5-FU resistance...
  83. ncbi Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
    Kyung-Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno-gu, Seoul, 110-744, South Korea
    Jpn J Clin Oncol 36:344-50. 2006
    ..Our results also suggest that it may be undesirable to use gemcitabine in patients with tumors not expressing p-Erk...
  84. ncbi Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer
    Dae-Young Kim
    Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongro-gu, Seoul 110-744, Korea
    Oncol Rep 14:207-11. 2005
    ....
  85. ncbi A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer
    Sook Ryun Park
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea
    Oncol Rep 12:1059-64. 2004
    ..In conclusion, the combination of Genexol and cisplatin was found to be an active and relatively well-tolerated regimen for the treatment of advanced gastric carcinoma...
  86. ncbi The signaling network of transforming growth factor beta1, protein kinase Cdelta, and integrin underlies the spreading and invasiveness of gastric carcinoma cells
    Mi Sook Lee
    Cancer Research Institute, College of Medicine, Seoul National University, Republic of Korea
    Mol Cell Biol 25:6921-36. 2005
    ....
  87. ncbi Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells
    Keun-Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Anticancer Res 26:3429-38. 2006
    ..Moreover, SK-7041 inhibited cancer cell proliferation more selectively than NHBE cell proliferation. CONCLUSIONS: These results suggest that SK-7041 may have potential anticancer activity...
  88. ncbi Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
    Jung Hyun Park
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 10:5271-81. 2004
    ..Therefore, based on isotype specificity and antitumor activity, SK-7041 and SK-7068 HDAC inhibitors are expected to be promising anticancer therapeutic agents and need additional clinical development...
  89. ncbi Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer
    Jee Hyun Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 20:806-10. 2005
    ..2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer...
  90. ncbi CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience
    Do Youn Oh
    Seoul National University Boramae Hospital, 425 Shindaebang dong, Dongjak Gu, 156 707, Seoul, South Korea
    Support Care Cancer 14:103-8. 2006
    ..We conducted this prospective observational study to characterize current CPR and do-not-resuscitate (DNR) practice among terminal cancer patients in South Korea...
  91. ncbi Artificial nutrition and hydration in terminal cancer patients: the real and the ideal
    Do Youn Oh
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, South Korea
    Support Care Cancer 15:631-6. 2007
    ..Administered calories and changes in these according to time and "DNR" (do-not-resuscitate) status were noted...
  92. ncbi Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
    Seock Ah Im
    Department of Internal Medicine, Cancer Research Institute, Seoul, Republic of Korea
    Diagn Mol Pathol 20:94-100. 2011
    ..2% vs. 43.3%, respectively; P=0.086). These findings suggest that further investigations of adjuvant therapy with HER2-targeted therapy for advanced GC are warranted...
  93. ncbi Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Young Tae Kim
    Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Center, Seoul, Republic of Korea
    Lung Cancer 59:111-8. 2008
    ..Whereas KRAS mutation was a poor prognostic factor, EGFR mutation was not, and its presence per se did not affect the clinical outcome of early lung cancer after surgical resection...
  94. ncbi Regulation of DeltaNp63alpha by tumor necrosis factor-alpha in epithelial homeostasis
    Hae Ock Lee
    Department of Biological Sciences and Research Center for Functional Cellulomics, Seoul National University, Korea
    FEBS J 274:6511-22. 2007
    ....
  95. ncbi Role of adjuvant chemoradiotherapy for ampulla of Vater cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 75:436-41. 2009
    ..To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer...
  96. ncbi Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Sae-Won Han
    Department of Internal Medicine and Pathology, Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 12:2538-44. 2006
    ..In addition to EGFR mutation, K-ras mutation and Akt phosphorylation aid in better prediction of gefitinib responsiveness in non-small-cell lung cancer...
  97. ncbi Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer
    Sae-Won Han
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Int J Cancer 113:109-15. 2005
    ..08-0.79, p = 0.018) and OS (HR 0.16, 95% CI 0.04-0.62, p = 0.008). These results support the assumption that gefitinib responsiveness might be predicted by activated EGFR downstream molecules such as p-Akt and p-Erk...
  98. ncbi A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer
    Tae-You Kim
    Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Korea
    Am J Clin Oncol 25:238-43. 2002
    ..293). In conclusion, induction PEV chemotherapy plus radiotherapy is superior to radiotherapy alone in high-risk subsets of unresectable LAD-NSCLC and therapeutic strategy should be based on the identification of prognostic factors...
  99. ncbi Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy
    Jae Jin Lee
    Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    Jpn J Clin Oncol 34:400-4. 2004
    ..CONCLUSION: The response rate to capecitabine was low in metastatic colorectal cancers that were refractory to 5-FU/LV-containing chemotherapy. However, disease stabilization was seen in a significant number of patients...
  100. ncbi Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells
    Tai Young Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of MedicineSeoul 110 744, Korea
    Exp Mol Med 40:639-46. 2008
    ..These results demonstrated the requirement of specific Sp1 sites and dependence of Sp1 and p300 for TSA-mediated activation of DLC-1 promoter...
  101. ncbi A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor
    Min Hee Ryu
    Department of Internal Medicine, Division of Oncology, Asan Medical Center, Songpa Gu, Seoul, Korea
    Oncology 76:326-32. 2009
    ..This prospective, multicenter, phase 2 study evaluated the efficacy and safety of imatinib mesylate and assessed KIT and PDGFRA gene mutation status in Korean patients with gastrointestinal stromal tumors (GISTs)...